Back

Kos appoints former Eli Lilly oncology CSO Michael Kalos as Venture Partner

Verifying
  • Kos Biotechnology Partners appointed Michael Kalos, PhD, as Venture Partner.
  • Kos manages a $123 million fund after its third closing in June 2026.
  • Michael Kalos co-invented CTL019, later approved as Kymriah, the first FDA-approved CAR-T therapy.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Kos appoints former Eli Lilly oncology CSO Michael Kalos as Venture Partner - CoinPost Terminal